{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:54Z","timestamp":1791305934414,"version":"4.3.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.contraception.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T10:37:37Z","timestamp":1273660657000},"page":"410-417","source":"Crossref","is-referenced-by-count":153,"title":["The use of newer progestins for contraception"],"prefix":"10.1016","volume":"82","author":[{"given":"Regine","family":"Sitruk-Ware","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2010.04.004_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","article-title":"Classification and pharmacology of progestins","volume":"61","author":"Schindler","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2010.04.004_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.maturitas.2008.11.011","article-title":"Pharmacological profile of progestins","volume":"61","author":"Sitruk-Ware","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestagens for contraceptive use","volume":"12","author":"Sitruk-Ware","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2010.04.004_bib4","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1073\/pnas.122225699","article-title":"Coactivator\/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486","volume":"99","author":"Liu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.contraception.2010.04.004_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1020072325818","article-title":"Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception","volume":"3","author":"Stanczyk","year":"2002","journal-title":"Rev Endocrin Metab Disord"},{"key":"10.1016\/j.contraception.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2165\/00003495-199651020-00002","article-title":"Comparative pharmacology of newer progestagens","volume":"51","author":"Kuhl","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2010.04.004_bib7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1124\/mol.108.054312","article-title":"Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins","volume":"75","author":"Petit-Topin","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.contraception.2010.04.004_bib8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.steroids.2003.08.008","article-title":"Conception and pharmacodynamic profile of drospirenone","volume":"68","author":"Elger","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2010.04.004_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13697130500330341","article-title":"Drospirenone in combination with estrogens: for contraception and hormone replacement therapy","volume":"8","author":"Oelkers","year":"2005","journal-title":"Climacteric"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2010.04.004_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130601114859","article-title":"Drospirenone and estradiol: a new option for the postmenopausal woman","volume":"10","author":"Archer","year":"2007","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"White","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.contraception.2010.04.004_bib14","first-page":"717","article-title":"An oral contraceptive with 3 approved indications","volume":"53","author":"Mishell","year":"2008","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1517\/14656566.8.7.989","article-title":"Drospirenone: a novel progestin","volume":"8","author":"Rapkin","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.contraception.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00404-008-0907-x","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure","volume":"280","author":"Yildizhan","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.contraception.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.contraception.2003.08.014","article-title":"An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone\/30 microg ethinylestradiol and 150 microg levonogestrel\/30 microg ethinylestradiol in Thai women","volume":"69","author":"Suthipongse","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/AOG.0b013e3181b46f54","article-title":"Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives","volume":"114","author":"Cronin","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.004_bib19","first-page":"9","article-title":"Pharmacology of nortestosterone derivatives","volume":"6","author":"Golbs","year":"2001","journal-title":"Menopause Rev"},{"key":"10.1016\/j.contraception.2010.04.004_bib20","series-title":"Progestins and antiprogestins in clinical practice","first-page":"101","year":"2000"},{"key":"10.1016\/j.contraception.2010.04.004_bib21","first-page":"17","article-title":"Pharmacology of estradiol valerate\/dienogest","volume":"6","author":"Teichmann","year":"2003","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2010.04.004_bib22","series-title":"Progestins and antiprogestins in clinical practice","first-page":"163","article-title":"Hybrid progestins: the example of dienogest","author":"Oettel","year":"2000"},{"key":"10.1016\/j.contraception.2010.04.004_bib23","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2165\/11202820-000000000-00000","article-title":"Estradiol valerate\/dienogest: in oral contraception","volume":"69","author":"Hoy","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2010.04.004_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0039-128X(03)00142-9","article-title":"The preclinical biology of a new potent and selective progestin: trimegestone","volume":"68","author":"Winneker","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2010.04.004_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/09513590701267727","article-title":"Preclinical and clinical properties of trimegestone: a potent and selective progestin","volume":"23","author":"Sitruk-Ware","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/09513599909167574","article-title":"The pharmacological profile of a novel norpregnance progestin (trimegestone)","volume":"13","author":"Philibert","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2010.04.004_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0039-128X(00)00120-3","article-title":"In-vitro characterization of trimegestone: a new potent and selective progestin","volume":"65","author":"Zhang","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2010.04.004_bib28","first-page":"2038","article-title":"Psychotropic effects of pregnane steroids in animal models of anxiety","volume":"26","author":"Root","year":"2000","journal-title":"Soc Neurosci"},{"key":"10.1016\/j.contraception.2010.04.004_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-5173(00)00357-4","article-title":"Physical evaluation of a new patch made of a progestomimetic in a silicone matrix","volume":"199","author":"Maillard-Salin","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1016\/j.contraception.2010.04.004_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0039-128X(00)00119-7","article-title":"Nestorone\u00ae: a progestin with a unique pharmacological profile","volume":"65","author":"Kumar","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2010.04.004_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0010-7824(90)90062-Z","article-title":"Potency and pharmacokinetics of gestagens","volume":"41","author":"Fotherby","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0010-7824(93)90117-P","article-title":"Pharmacokinetics and bioavailability of ST 1435 administered by different routes","volume":"48","author":"Noe","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0010-7824(94)00006-I","article-title":"Clinical trial with Nestorone\u00ae subdermal contraceptive implants","volume":"51","author":"Daz","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0010-7824(90)90082-7","article-title":"Milk and plasma concentrations of the progestin ST 1435 in women treated parenterally with ST 1435","volume":"42","author":"Lahteenmaki","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib35","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.ajog.2004.01.056","article-title":"New delivery systems in contraception: vaginal rings","volume":"190","author":"Johansson","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.004_bib36","first-page":"122","article-title":"Contraceptive vaginal rings releasing Nestorone and ethinyl-estradiol","volume":"71","author":"Sivin","year":"2005","journal-title":"A one-year dose-finding trial Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0039-128X(03)00140-5","article-title":"Nestorone: clinical applications for contraception and HRT","volume":"68","author":"Sitruk-Ware","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2010.04.004_bib38","series-title":"Contraception: newer pharmacological agents, devices, and delivery systems","first-page":"101","article-title":"Transdermal contraceptive systems: innovative technology for the twenty-first century","author":"Croxatto","year":"1992"},{"key":"10.1016\/j.contraception.2010.04.004_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.contraception.2007.08.006","article-title":"An initial pharmacokinetic study with Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive","volume":"76","author":"Fraser","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0010-7824(01)00259-1","article-title":"Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women","volume":"64","author":"Massai","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0960-0760(95)00171-U","article-title":"Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity","volume":"55","author":"Catherino","year":"1995","journal-title":"Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2010.04.004_bib42","first-page":"70","article-title":"Antiandrogenic properties of nomegestrol acetate","volume":"45","author":"Duc","year":"1995","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.contraception.2010.04.004_bib43","first-page":"459","article-title":"Nomegestrol acetate: clinical pharmacology","volume":"61","author":"Lello","year":"2009","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.contraception.2010.04.004_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0010-7824(93)90112-K","article-title":"One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant)","volume":"47","author":"Coutinho","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0015-0282(16)58204-1","article-title":"Effects of a single contraceptive silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years","volume":"65","author":"Barbosa","year":"1996","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.04.004_bib46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.contraception.2006.07.013","article-title":"Effects of a single silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year","volume":"74","author":"Barbosa","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1471-0528.1987.tb02322.x","article-title":"Effect of nomegestrol acetate, a new 19 nor-progesterone derivative, on pituitary\u2013ovarian function in women","volume":"94","author":"Bazin","year":"1987","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2010.04.004_bib48","article-title":"Synergistic effect of 17 estradiol and nomegestrol acetate used in a new monophasic oral contraceptive","author":"Chabbert-Buffet","year":"2009"},{"key":"10.1016\/j.contraception.2010.04.004_bib49","first-page":"339","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"b2890","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2010.04.004_bib50","first-page":"339","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"b2921","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2010.04.004_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib52","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2007-0026","article-title":"Effects of oral and trans-vaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, cross-over study","volume":"2","author":"Sitruk-Ware","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2010.04.004_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajog.2005.12.007","article-title":"Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables","volume":"195","author":"Rad","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.004_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7836.2008.02863.x","article-title":"Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor","volume":"6","author":"van Vliet","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.contraception.2010.04.004_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/13697130802403994","article-title":"Effects of drospirenone on cardiovascular markers in human aortic endothelial cells","volume":"12","author":"Seeger","year":"2009","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2010.04.004_bib56","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.contraception.2005.09.015","article-title":"A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol","volume":"73","author":"Kluft","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.contraception.2008.06.015","article-title":"Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters","volume":"78","author":"Wiegratz","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.maturitas.2009.01.004","article-title":"Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone","volume":"62","author":"Hellgren","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2010.04.004_bib59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH07-12-0746","article-title":"Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)\/dydrogesterone and estradiol (2 mg)\/trimegestone","volume":"100","author":"Norris","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2010.04.004_bib60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0010-7824(01)00310-9","article-title":"Effect of dienogest-containing oral contraceptives on lipid metabolism","volume":"65","author":"Wiegratz","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib61","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0010-7824(91)90080-Y","article-title":"Effects of nomegestrol acetate (5 mg\/d) on hormonal, metabolic and hemostatic parameters in premenopausal women","volume":"44","author":"Basdevant","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1472-8206.1987.tb00562.x","article-title":"Effects of progestogens on lipemia and lipolysis in rat: effects of progesterone, megestrol acetate, norethindrone acetate, and nomegestrol acetate","volume":"1","author":"Hazard","year":"1987","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.contraception.2010.04.004_bib63","first-page":"99","article-title":"The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function","volume":"80","author":"Szlendak-Sauer","year":"2009","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.contraception.2010.04.004_bib64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09513590701325731","article-title":"Influence of a new oral contraceptive with drospirenone on lipid metabolism","volume":"23","author":"Taneepanichskul","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2010.04.004_bib65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.contraception.2009.01.005","article-title":"Selective effect of chlormadinone acetate on brain allopregnanolone and opioids content","volume":"80","author":"Pluchino","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.004_bib66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsbmb.2008.02.002","article-title":"Effects of nomegestrol acetate administration on central and peripheral beta-endorphin and allopregnanolone in ovx rats","volume":"110","author":"Lenzi","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2010.04.004_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.gme.0000230348.05745.7d","article-title":"Drospirenone increases central and peripheral beta-endorphin in ovariectomized female rats","volume":"14","author":"Genazzani","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.contraception.2010.04.004_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jsbmb.2009.04.004","article-title":"Central modifications of allopregnanolone and beta-endorphin following subcutaneous administration of Nestorone","volume":"116","author":"Lenzi","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2010.04.004_bib69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/en.143.1.205","article-title":"Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate","volume":"143","author":"Nilsen","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.contraception.2010.04.004_bib70","article-title":"Progestins induce myelination and remyelination in slice cultures of murine cerebellum","author":"Ghoumari","year":"2009"},{"key":"10.1016\/j.contraception.2010.04.004_bib71","unstructured":"International Agency for Research on Cancer (IARC) (Centre International de Recherche sur le Cancer (CIRC)). Web site: http:\/\/www.iarc.fr. IARC Carcinogen monographs: http:\/\/monographs.iarc.fr\/index.php. Accessed on 8\/12\/09."},{"key":"10.1016\/j.contraception.2010.04.004_bib72","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2004.06.007","article-title":"Exogenous progestagens and the human breast","volume":"49","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2010.04.004_bib73","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0960-9776(03)00003-1","article-title":"Effects of a progestogen on normal human breast epithelial cell apoptosis in vitro and in vivo","volume":"12","author":"Desreux","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.contraception.2010.04.004_bib74","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.maturitas.2008.10.017","article-title":"Progestogen use in women approaching the menopause and breast cancer risk","volume":"62","author":"Campagnoli","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2010.04.004_bib75","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1158\/1055-9965.EPI-08-0056","article-title":"Progestagens use before menopause and breast cancer risk according to histology and hormone receptors","volume":"17","author":"Fabre","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.contraception.2010.04.004_bib76","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1524-4741.2008.00621.x","article-title":"Effect of combined oral contraceptives on breast epithelial proliferation in young women","volume":"14","author":"Garcia y Narvaiza","year":"2008","journal-title":"Breast J"},{"key":"10.1016\/j.contraception.2010.04.004_bib77","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2407-8-166","article-title":"Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and Nestorone on breast cancer cell migration and invasion","volume":"8","author":"Fu","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.contraception.2010.04.004_bib78","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.maturitas.2006.07.003","article-title":"Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells","volume":"56","author":"Xu","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2010.04.004_bib79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejogrb.2005.12.004","article-title":"The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells","volume":"129","author":"Kr\u00e4mer","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2010.04.004_bib80","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jsbmb.2005.06.032","article-title":"Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells","volume":"97","author":"Bray","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2010.04.004_bib81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/09513590701585003","article-title":"Progestins and breast cancer","volume":"23","author":"Pasqualini","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2010.04.004_bib82","first-page":"2827","article-title":"Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues","volume":"25","author":"Chetrite","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.contraception.2010.04.004_bib83","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1096\/fj.06-7518com","article-title":"Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer","volume":"21","author":"Birrell","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.contraception.2010.04.004_bib84","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2010.04.004_bib85","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/bmj.c927","article-title":"Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study","volume":"340","author":"Hannaford","year":"2010","journal-title":"BMJ"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T23:53:10Z","timestamp":1559087590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782410001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0010782410001411"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2010.04.004","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}